KRON Stock Price, Kronos Bio Inc Quote, Chart

Market Summary

USD1.00+0.02

Delayed

2.04%

KRON Stock Price

View Fullscreen

KRON RSI Chart

KRON Valuation

Market Cap

60.1M

Price/Earnings (Trailing)

-0.52

Price/Sales (Trailing)

6.72

Price/Free Cashflow

-0.62

KRON Price/Sales (Trailing)

KRON Profitability

Return on Equity

-84.98%

Return on Assets

-63.61%

Free Cashflow Yield

-161.57%

KRON Fundamentals

KRON Revenue

Revenue (TTM)

8.9M

Rev. Growth (Yr)

-9.71%

Rev. Growth (Qtr)

0.59%

KRON Earnings

Earnings (TTM)

-116.4M

Earnings Growth (Yr)

-14.18%

Earnings Growth (Qtr)

-18.32%

Breaking Down KRON Revenue

Last 7 days

-2.0%

Last 30 days

-3.8%

Last 90 days

-2.0%

Trailing 12 Months

-44.1%

How does KRON drawdown profile look like?

KRON Financial Health

Current Ratio

8.32

KRON Investor Care

Shares Dilution (1Y)

4.28%

Diluted EPS (TTM)

-1.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.9M	0	0	0
2023	6.1M	7.9M	9.0M	9.2M
2022	330.0K	871.0K	2.1M	3.9M
2021	635.0K	502.0K	372.0K	320.0K
2020	751.0K	800.0K	849.0K	898.0K
2019	0	0	0	702.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kronos Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 21, 2024	lin charles y	sold	-12,684	1.0539	-12,036	sr vp, research & development
Feb 21, 2024	frisbee allison	sold	-12,757	1.0539	-12,105	sr vp, corp operations & legal
Feb 21, 2024	olek elizabeth a	sold	-7,765	1.0539	-7,368	sr vp, clinical science
Feb 15, 2024	bischofberger norbert w	acquired	-	-	270,339	president & ceo
Jan 04, 2024	dinsmore christopher	sold	-8,718	1.1836	-7,366	chief scientific officer
Jan 04, 2024	dimartino jorge	sold	-14,213	1.1836	-12,009	chief medical officer & vp
Jan 04, 2024	kosacz barbara	sold	-12,636	1.1836	-10,676	coo & general counsel
Dec 12, 2023	dimartino jorge	sold	-22,663	1.305	-17,367	chief medical officer & vp
Dec 12, 2023	dinsmore christopher	sold	-13,091	1.305	-10,032	chief scientific officer
Nov 17, 2023	bischofberger norbert w	bought	106,162	1.084	97,935	president & ceo

Which funds bought or sold KRON recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-3.51	83.00	23,932	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	7.26	42,409	409,503	0.01%
May 15, 2024	Royal Bank of Canada	reduced	-47.87	-	-	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-8.9	-1,290	23,264	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-4.32	-1,218	246,232	-%
May 15, 2024	D. E. Shaw & Co., Inc.	sold off	-100	-318,734	-	-%
May 15, 2024	MORGAN STANLEY	reduced	-1.82	1,017	49,189	-%
May 15, 2024	KENNEDY CAPITAL MANAGEMENT LLC	added	6.31	14,293	149,579	-%
May 15, 2024	STATE STREET CORP	unchanged	-	8,915	231,791	-%
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	reduced	-79.76	-289,695	77,217	-%

Are Funds Buying or Selling KRON?

Are funds buying KRON calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KRON

No. of Funds

Unveiling Kronos Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 27, 2023	bischofberger norbert w	17.4%	10,624,737	SC 13D
Jul 07, 2023	blackrock inc.	2.4%	1,397,345	SC 13G/A
Feb 13, 2023	capital world investors	0.0%	0	SC 13G/A
Feb 13, 2023	omega fund v, l.p.	6.71%	3,818,283	SC 13G/A
Feb 09, 2023	vanguard group inc	2.64%	1,504,922	SC 13G/A
Feb 01, 2023	blackrock inc.	5.6%	3,206,885	SC 13G/A
Feb 17, 2022	bischofberger norbert w	10.5%	5,935,160	SC 13G/A
Feb 17, 2022	belldegrun arie	6.1%	3,444,889	SC 13G/A
Feb 11, 2022	capital world investors	5.6%	3,151,414	SC 13G
Feb 11, 2022	capital research global investors	0.0%	0	SC 13G/A

Recent SEC filings of Kronos Bio Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Mar 21, 2024	10-K	Annual Report
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	S-8	Employee Benefits Plan
Mar 07, 2024	8-K	Current Report
Mar 05, 2024	8-K	Current Report

Peers (Alternatives to Kronos Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Kronos Bio Inc News

Latest updates

Kronos Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	0.6%	2,036	2,024	2,451	2,427	2,255	1,900	1,282	627	102	72.00	70.00	86.00	92.00	124	200	219	355	333	311
Operating Expenses	16.5%	34,514	29,630	34,742	34,032	29,714	33,682	33,538	33,530	36,365	62,406	33,673	29,141	26,178	21,088	20,809	8,798	7,349	-	4,323
S&GA Expenses	-100.0%	-	10,926	9,398	11,359	10,056	10,514	10,135	10,824	11,927	11,587	8,985	9,339	8,584	7,963	4,054	1,623	1,154	-	797
R&D Expenses	-24.0%	14,222	18,704	25,344	22,673	19,658	23,168	23,403	22,706	24,438	50,819	24,688	19,802	17,594	13,125	16,755	7,175	6,195	-	3,526
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,889	-	1.00	-	1.00
Net Income	-18.3%	-29,958	-25,320	-31,374	-29,741	-26,238	-31,782	-32,256	-32,903	-36,263	-62,334	-33,603	-29,055	-26,086	-88,444	-39,713	-8,579	-6,995	-16,117	-4,013
Net Income Margin	-5.8%	-13.02*	-12.30*	-13.19*	-15.26*	-20.31*	-34.06*	-78.62*	-189.56*	-488.65*	-472.12*	-476.31*	-365.14*	-	-	-	-	-	-	-
Free Cashflow	4.6%	-23,906	-25,055	-22,800	-25,333	-6,073	-22,580	-22,467	-22,606	-23,850	-59,000	-21,066	-21,615	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-14.2%	183	213	238	261	289	295	318	341	366	391	448	472	488	512	263	103
Current Assets	-11.4%	158	179	192	224	232	244	265	275	311	348	403	424	405	420	213	93.00
Cash Equivalents	-25.0%	48.00	64.00	58.00	44.00	62.00	76.00	67.00	86.00	149	200	217	186	141	250	156	33.00
Net PPE	-20.8%	8.00	10.00	11.00	12.00	13.00	13.00	-	-	-	15.00	-	-	-	-	-	-
Liabilities	-15.1%	46.00	54.00	59.00	57.00	63.00	50.00	50.00	49.00	49.00	46.00	49.00	48.00	43.00	46.00	216	-
Current Liabilities	-22.9%	19.00	25.00	26.00	22.00	25.00	21.00	20.00	18.00	17.00	14.00	15.00	13.00	11.00	13.00	184	3.00
Shareholder's Equity	-13.9%	137	159	179	203	226	244	268	292	317	345	399	424	445	466	-	-
Retained Earnings	-5.9%	-538	-508	-483	-452	-422	-396	-364	-332	-299	-262	-200	-167	-137	-111	-78.75	-23.46
Additional Paid-In Capital	1.2%	676	668	662	656	648	641	633	625	616	608	600	591	583	577	2.00	0.00
Shares Outstanding	1.9%	60.00	59.00	58.00	58.00	57.00	57.00	56.00	56.00	56.00	56.00	55.00	54.00	-	-	-	-
Float	-	-	-	-	48.00	-	-	-	205	-	-	-	1,300	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	4.5%	-23,899	-25,024	-22,586	-25,025	-5,947	-22,528	-22,394	-22,520	-23,484	-58,522	-20,140	-20,264	-18,998	-15,630	-10,286	-4,930	-7,066	-	-	-
Share Based Compensation	-35.7%	3,327	5,173	6,296	6,906	6,607	7,689	7,461	8,207	7,788	7,404	7,137	6,432	5,238	2,019	1,253	293	188	-	23.00	-
Cashflow From Investing	-81.7%	5,770	31,560	35,789	5,374	-6,355	31,736	3,107	-40,729	-26,336	38,749	50,094	63,030	-88,149	-158,755	-20,781	13,991	5,310	-	-	-
Cashflow From Financing	-100.0%	-	191	-	376	-	-716	628	410	529	1,050	1,381	1,444	585	266,199	149,297	105	12.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KRON Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 2,520	$ 1,221
Operating expenses:
Research and development	14,222	19,658
General and administrative	7,506	10,056
Impairment of long-lived assets and restructuring	12,786	0
Total operating expenses	34,514	29,714
Loss from operations	(31,994)	(28,493)
Other income (expense), net:
Interest income and other expense, net	2,036	2,255
Total other income (expense), net	2,036	2,255
Net loss	(29,958)	(26,238)
Other comprehensive loss:
Net unrealized gain (loss) on available-for-sale securities	(68)	432
Net comprehensive loss	$ (30,026)	$ (25,806)
Net loss per share, basic (in dollars per share)	$ (0.50)	$ (0.46)
Net loss per share, diluted (in dollars per share)	$ (0.50)	$ (0.46)
Weighted-average shares of common stock, basic (in shares)	59,521	57,147
Weighted-average shares of common stock, diluted (in shares)	59,521	57,147

KRON Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

^[1]

Current assets:

Cash and cash equivalents

$ 46,197

$ 64,326

Short-term investments

105,787

108,671

Prepaid expenses and other current assets

6,375

5,781

Total current assets

158,359

178,778

Long-term investments

0

1,989

Property and equipment, net

8,115

10,252

Operating lease right-of-use assets

13,902

19,657

Restricted cash

2,026

Other noncurrent assets

577

Total assets

182,979

213,279

Current liabilities:

Accounts payable

2,226

883

Accrued expenses

4,987

10,931

Current portion of operating lease liabilities

3,017

2,893

Current portion of deferred revenue

8,670

9,584

Current portion of other liabilities

132

404

Total current liabilities

19,032

24,695

Noncurrent operating lease liabilities

24,457

25,379

Noncurrent deferred revenue

2,522

4,127

Total liabilities

46,011

54,201

Commitments and contingencies (Note 9)

Stockholders’ equity:

Preferred stock, $0.001 par value; 10,000 authorized; no shares issued and outstanding.

Common stock, $0.001 par value, 200,000 authorized as of March 31, 2024 and December 31, 2023; 60,089 and 58,946 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.

60

59

Additional paid-in capital

675,776

667,861

Accumulated deficit

(538,819)

(508,861)

Accumulated other comprehensive income (loss)

(49)

19

Total stockholders' equity

136,968

159,078

Total liabilities and stockholders’ equity

$ 182,979

$ 213,279

[1]	The balance sheet as of December 31, 2023 is derived from the audited financial statements as of that date.

About Kronos Bio Inc

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.

CEO	Dr. Norbert W. Bischofberger Ph.D.
WEBSITE	https://kronosbio.com
INDUSTRY	Biotechnology
EMPLOYEES	104

Kronos Bio Inc Frequently Asked Questions

What is the ticker symbol for Kronos Bio Inc? What does KRON stand for in stocks?

KRON is the stock ticker symbol of Kronos Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kronos Bio Inc (KRON)?

As of Fri May 17 2024, market cap of Kronos Bio Inc is 60.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRON stock?

You can check KRON's fair value in chart for subscribers.

What is the fair value of KRON stock?

You can check KRON's fair value in chart for subscribers. The fair value of Kronos Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kronos Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KRON so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kronos Bio Inc a good stock to buy?

The fair value guage provides a quick view whether KRON is over valued or under valued. Whether Kronos Bio Inc is cheap or expensive depends on the assumptions which impact Kronos Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRON.

What is Kronos Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, KRON's PE ratio (Price to Earnings) is -0.52 and Price to Sales (PS) ratio is 6.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRON PE ratio will change depending on the future growth rate expectations of investors.